Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015
Status:
Terminated
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the extension phase is to evaluate the long-term safety and tolerability of
buprenorphine transdermal system (BTDS). Subjects begin the extension phase on BTDS 5 mcg/h
and may up- or down-titrate the dose [up to BTDS 20 micrograms (mcg) / hour (h)] depending on
adequate pain relief and tolerability.